The DCIS-IBC guide board on predicting postoperative upgrading in breast ductal carcinoma in situ: clinical insights from a multicenter study

DCIS-IBC指南委员会关于预测乳腺导管原位癌术后升级的指南:一项多中心研究的临床见解

阅读:1

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) carries a significant risk of postoperative upgrading to invasive breast cancer (IBC), yet existing prediction models lack validation in Asian populations. This study aimed to develop and validate a population-specific nomogram to preoperatively predict DCIS-to-IBC upgrading in Asian patients. METHODS: A multicenter retrospective cohort of 465 Asian women diagnosed with DCIS by core needle biopsy (2015-2021) was analyzed. Patients were randomly divided into training (n = 257), internal validation (n = 110), and external validation cohorts (n = 98). Predictors were selected via LASSO regression and multivariable logistic regression. Model performance was assessed using AUC, calibration curves, and decision curve analysis (DCA). An interactive online nomogram was developed for clinical application. RESULTS: Postoperative upgrading occurred in 49.46% (230/465) of patients. Four independent predictors were identified: palpable mass (OR = 2.55, p = 0.096), lesion palpability (OR = 2.58, p = 0.043), low nuclear grade (OR = 0.55, p = 0.098), and suspected invasion (OR = 6.59, p < 0.001). The nomogram demonstrated robust discrimination in the training cohort (AUC = 0.802, 95% CI 0.748-0.856), with maintained performance in internal validation (AUC = 0.753) and acceptable generalizability in external validation (AUC = 0.680). DCA confirmed clinical utility across risk thresholds. The dynamic nomogram ( https://duancl777.shinyapps.io/dynnomapp/ ) enabled real-time risk stratification. CONCLUSIONS: The DCIS-IBC Guide Board is the first Asian-specific model integrating clinicopathological predictors to identify high-risk DCIS patients. It facilitates personalized decisions, such as omitting sentinel lymph node biopsy while reducing overtreatment. Although external validation showed moderate performance, this tool addresses critical population heterogeneity and enhances preoperative risk assessment. Prospective multicenter studies are warranted to optimize generalizability and explore multimodal predictors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。